The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 20 April 2026•Updated 21 April 2026•

1 min read

Psyence BioMed Secures Exclusive Global Supply Chain for Pharmaceutical Ibogaine

Key Facts

1Psyence BioMed announced its position as the world's only licensed pharmaceutical-grade ibogaine supplier at the source.

2The company established a GMP-compliant supply chain through investment and collaboration with PsyLabs.

Psyence BioMed has established itself as a premier licensed supplier of pharmaceutical-grade ibogaine through a GMP-compliant supply chain. The competitive landscape is evolving as Optimi Health Corp recently launched its own Ibogaine Initiative to manufacture and supply the substance under a Health Canada-licensed platform. This industry growth coincides with a new U.S. Executive Order signaling a federal policy framework designed to accelerate research and patient access to psychedelic drug products. Ibogaine is currently under intense clinical investigation for treating opioid use disorder, PTSD, and traumatic brain injury. These developments highlight a significant shift toward the medical validation of psychedelic treatments. Consequently, Psyence BioMed faces a more dynamic market as regulatory pathways in North America become more defined.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Entry of a new competitor (Optimi Health) into the ibogaine supply market and the issuance of a U.S. Executive Order supporting psychedelic research.